- Home
- ANVS vs EYEN Comparison
ANVS vs EYEN Comparison
Compare ANVS & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- EYEN
- Stock Information
- Founded
- ANVS 2008
- EYEN 2014
- Country
- ANVS United States
- EYEN United States
- Employees
- ANVS N/A
- EYEN N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- EYEN Health Care
- Exchange
- ANVS Nasdaq
- EYEN Nasdaq
- Market Cap
- ANVS 54.6M
- EYEN 2.9M
- IPO Year
- ANVS 2020
- EYEN 2018
- Fundamental
- Price
- ANVS $2.18
- EYEN $10.22
- Analyst Decision
- ANVS Strong Buy
- EYEN Hold
- Analyst Count
- ANVS 5
- EYEN 4
- Target Price
- ANVS $30.25
- EYEN $2.00
- AVG Volume (30 Days)
- ANVS 616.9K
- EYEN 10.0M
- Earning Date
- ANVS 08-14-2025
- EYEN 08-11-2025
- Dividend Yield
- ANVS N/A
- EYEN N/A
- EPS Growth
- ANVS N/A
- EYEN N/A
- EPS
- ANVS N/A
- EYEN N/A
- Revenue
- ANVS N/A
- EYEN $67,063.00
- Revenue This Year
- ANVS N/A
- EYEN $7,680.45
- Revenue Next Year
- ANVS N/A
- EYEN $315.38
- P/E Ratio
- ANVS N/A
- EYEN N/A
- Revenue Growth
- ANVS N/A
- EYEN 663.82
- 52 Week Low
- ANVS $1.11
- EYEN $0.85
- 52 Week High
- ANVS $17.88
- EYEN $124.80
- Technical
- Relative Strength Index (RSI)
- ANVS 43.14
- EYEN 69.20
- Support Level
- ANVS $2.52
- EYEN $3.68
- Resistance Level
- ANVS $3.18
- EYEN $11.40
- Average True Range (ATR)
- ANVS 0.31
- EYEN 2.03
- MACD
- ANVS -0.10
- EYEN 0.58
- Stochastic Oscillator
- ANVS 5.38
- EYEN 73.25
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.